PDCD1 and cancer: Immune checkpoint inhibition (CPI) trials with other cancers have mainly focused on antibody-targeting programmed cell death 1 protein (PD-1), programmed cell death ligand 1 (PD-L1) and cytotoxic T-lymphocyte antigen-4 (CTLA-4) [21,58,59,60].